Race Oncology Ltd. (AU:RAC)
ASX:RAC
Want to see AU:RAC full AI Analyst Report?
RAC Stock Chart & Stats
AU$2.70
-AU$0.03(-2.27%)
At close: 4:00 PM EST
AU$2.70
-AU$0.03(-2.27%)
Day’s Range― - ―
52-Week RangeAU$1.12 - AU$4.90
Previous CloseN/A
Volume68.10K
Average Volume (3M)373.28K
Market Cap
AU$493.20M
Enterprise ValueAU$437.45M
Total Cash (Recent Filing)AU$20.94M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.66
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding188,964,580
10 Day Avg. Volume310,625
30 Day Avg. Volume373,283
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)12.69
Price to Sales (P/S)33.63
P/FCF Ratio-44.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero debt materially reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs and partnerships from equity or grants. A debt-free structure is a durable buffer for clinical-stage biotech, preserving optionality during multi-period development timelines.
Gross Margin ImprovementA materially stronger gross margin in FY2025 indicates higher revenue quality or lower direct costs for core programs. If sustained, improved gross margins support better operational leverage as revenue grows and reduce the hurdle for the business to reach positive operating margins over a multi-quarter development horizon.
Improving Cash Burn TrendA reduction in operating and free cash outflows shows management cost discipline and a trajectory toward narrower losses. Continued improvement in cash burn enhances runway and reduces the frequency/size of future financings, materially affecting the company's ability to execute longer-term clinical programs.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business is not self-funding its development programs. Over several quarters this forces reliance on external funding, increases dilution risk, and constrains strategic choices, a durable headwind until sustainable positive cash generation is achieved.
Volatile Revenue TrajectorySharp and unpredictable revenue swings impair planning for R&D and commercialization. For a clinical-stage biotech, uneven commercialization or one-off receipts make forecasting cash needs harder and delay the establishment of recurring revenue streams required for long-term viability.
Equity Erosion And Negative ROEDeclining equity and materially negative ROE indicate shareholder capital is being consumed rather than generating returns. Over time this erodes balance-sheet resilience, increases the probability of dilutive capital raises, and constrains ability to invest in late-stage trials or commercial scaling without external support.
Race Oncology Ltd. News
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$1.11 and its highest was AU$4.90 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$493.20M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 103 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 188,964,580 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.646%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Race Oncology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 98%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$110.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.34%
12-Months-Change
Fundamentals
Return on Equity
-47.44%
Trailing 12-Months
Asset Growth
14.28%
Trailing 12-Months
Company Description
Race Oncology Ltd.
Race Oncology Limited operates as a precision oncology company in Australia. The company is developing Zantrene, a potent small molecule inhibitor of the fatso/fat mass and obesity associated protein to treat for melanoma and clear cell renal cell carcinoma, as well as acute myeloid leukaemia, breast, and ovarian cancers, which is in Phase II/III clinical trial. It has a preclinical research program with the University of Newcastle for investigating Zantrene; and strategic collaboration with the University of Wollongong to evaluate Zantrene formulations. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.
Technical Analysis
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---